{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T07:32:11Z","timestamp":1777879931307,"version":"3.51.4"},"reference-count":17,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2018,11,13]],"date-time":"2018-11-13T00:00:00Z","timestamp":1542067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Infection"],"published-print":{"date-parts":[[2019,1]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>Cefoxitin has a good in vitro activity and stability in resistance to hydrolysis by extended-spectrum beta-lactamases and is a good candidate for the treatment of urinary tract infection. However, data are scarce regarding its use in clinical practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We conducted a retrospective study from September 2014 to November 2017, in a tertiary care hospital in Garches (France). We gathered all prescriptions of cefoxitin for urinary tract infection due to extended-spectrum beta-lactamase isolates. We compared the clinical outcomes between Escherichia coli and Klebsiella pneumoniae extended-spectrum-beta-lactamase-producing isolates after a 90-day follow-up. When available, we assessed whether cefoxitin-based regimen was associated with an emergence of resistance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The treatment of 31 patients with a mean age of 60 \u00b1 18 years was analyzed. We observed a clinical cure of 96.7% ( n = 30\/31) at day 30 and of 81.2% ( n = 13\/16) and 85.7% (12\/14) at day 90 for extended-spectrum beta-lactamase Escherichia coli and Klebsiella pneumoniae isolates, respectively ( p = 0.72). No adverse events were reported. One patient who relapsed carried a Klebsiella pneumoniae isolate that became intermediate to cefoxitin in the follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>In a period of major threat with a continuous increase of extended-spectrum beta-lactamase obliging to a policy of carbapenem-sparing regimens, it seems detrimental to deprive physicians of using cefoxitin for extended-spectrum beta-lactamase Enterobacteriaceae for the treatment of urinary tract infection while our data show its efficacy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/2049936118811053","type":"journal-article","created":{"date-parts":[[2018,11,13]],"date-time":"2018-11-13T11:06:20Z","timestamp":1542107180000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy of cefoxitin for the treatment of urinary tract infection due to extended-spectrum-beta-lactamase-producing\n                    <i>Escherichia coli<\/i>\n                    and\n                    <i>Klebsiella pneumoniae<\/i>\n                    isolates"],"prefix":"10.1177","volume":"6","author":[{"given":"Olivia","family":"Senard","sequence":"first","affiliation":[{"name":"Maladies Infectieuses, H\u00f4pital Universitaire Raymond-Poincar\u00e9, AP-HP, Garches, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fr\u00e9d\u00e9rique","family":"Bouchand","sequence":"additional","affiliation":[{"name":"Pharmacie Hospitali\u00e8re, H\u00f4pital Universitaire Raymond-Poincar\u00e9, AP-HP, Garches, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurene","family":"Deconinck","sequence":"additional","affiliation":[{"name":"Maladies Infectieuses, H\u00f4pital Universitaire Raymond-Poincar\u00e9, AP-HP, Garches, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morgan","family":"Matt","sequence":"additional","affiliation":[{"name":"Maladies Infectieuses, H\u00f4pital Universitaire Raymond-Poincar\u00e9, AP-HP, Garches, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lesly","family":"Fellous","sequence":"additional","affiliation":[{"name":"Pharmacie Hospitali\u00e8re, H\u00f4pital Universitaire Raymond-Poincar\u00e9, AP-HP, Garches, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Rottman","sequence":"additional","affiliation":[{"name":"Laboratoire de Microbiologie, H\u00f4pital Universitaire Raymond-Poincar\u00e9, AP-HP, Garches, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Perronne","sequence":"additional","affiliation":[{"name":"Maladies Infectieuses, H\u00f4pital Universitaire Raymond-Poincar\u00e9, AP-HP, Garches, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aur\u00e9lien","family":"Dinh","sequence":"additional","affiliation":[{"name":"Maladies Infectieuses, H\u00f4pital Universitaire Raymond-Poincar\u00e9, AP-HP, Garches, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Davido","sequence":"additional","affiliation":[{"name":"Maladies Infectieuses, H\u00f4pital Universitaire Raymond-Poincar\u00e9, AP-HP, Garches, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2018,11,13]]},"reference":[{"key":"bibr1-2049936118811053","volume-title":"Annual epidemiological report 2014: antimicrobial resistance and healthcare-associated infections","author":"European Centre for Disease Prevention and Control","year":"2015"},{"key":"bibr2-2049936118811053","first-page":"221","volume":"89","author":"Forsgren A.","year":"1981","journal-title":"Acta Pathol Microbiol Scand B"},{"key":"bibr3-2049936118811053","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.34.5.858"},{"key":"bibr4-2049936118811053","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.06233-11"},{"key":"bibr5-2049936118811053","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/159.5.1005"},{"key":"bibr6-2049936118811053","doi-asserted-by":"publisher","DOI":"10.4103\/0255-0857.13867"},{"key":"bibr7-2049936118811053","unstructured":"Institut de veille Sanitaire. Surveillance des bact\u00e9ries multir\u00e9sistantes dans les \u00e9tablissements de sant\u00e9 en France. R\u00e9seau BMR \u2013 Raisin \u2013 R\u00e9sultats 2013, http:\/\/invs.santepubliquefrance.fr\/Publications-et-outils\/Rapports-et-syntheses\/Maladies-infectieuses\/2015\/Surveillance-des-bacteries-multiresistantes-dans-les-etablissements-de-sante-en-France (2015, accessed October 2016)."},{"key":"bibr8-2049936118811053","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.41.7.3142-3146.2003"},{"key":"bibr9-2049936118811053","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9681(87)90171-8"},{"key":"bibr10-2049936118811053","unstructured":"Soci\u00e9t\u00e9 de Pathologie Infectieuse de Langue Francaise (SPILF). Diagnostic et antibioth\u00e9rapie des infections urinaires bact\u00e9riennes communautaires de l\u2019adulte, 2015, http:\/\/www.infectiologie.com\/UserFiles\/File\/spilf\/recos\/infections-urinaires-spilf.pdf"},{"key":"bibr11-2049936118811053","doi-asserted-by":"publisher","DOI":"10.3109\/23744235.2015.1062133"},{"key":"bibr12-2049936118811053","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2018.01.008"},{"key":"bibr13-2049936118811053","doi-asserted-by":"publisher","DOI":"10.1016\/j.medmal.2016.04.008"},{"key":"bibr14-2049936118811053","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2017.09.013"},{"key":"bibr15-2049936118811053","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00701-15"},{"key":"bibr16-2049936118811053","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02509-14"},{"key":"bibr17-2049936118811053","unstructured":"European Committee on Antimicrobial Susceptibility Testing: breakpoint tables for interpretation of MICs and zone diameters, http:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Breakpoint_tables\/v_7.1_Breakpoint_Tables.pdf"}],"container-title":["Therapeutic Advances in Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2049936118811053","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/2049936118811053","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2049936118811053","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:57:21Z","timestamp":1777593441000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/2049936118811053"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,13]]},"references-count":17,"alternative-id":["10.1177\/2049936118811053"],"URL":"https:\/\/doi.org\/10.1177\/2049936118811053","relation":{},"ISSN":["2049-9361","2049-937X"],"issn-type":[{"value":"2049-9361","type":"print"},{"value":"2049-937X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,13]]},"article-number":"2049936118811053"}}